β2-adrenergic agonist protects human endothelial cells from hypoxia/reoxygenation injury in vitro
Authors:
- Julien PottecherJPJulien Pottecher
- Gaëlle CheissonGCGaëlle Cheisson
- Olivier HuetOHOlivier Huet
- Christian LaplaceCLChristian Laplace
- Eric VicautEVEric Vicaut
- Jean X. MazoitJMJean X. Mazoit
- Dan BenhamouDBDan Benhamou
- Jacques DuranteauJDJacques Duranteau
- 1 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 34 (1) , 165-172
Abstract
Circulatory shock results in hypoxia/reoxygenation processes that lead to the release of reactive oxygen species, endothelial injury, and multiple organ failure. Previous data suggest that beta2-adrenergic agonists prevent endothelial dysfunction. The study aimed at determining whether the beta2-adrenergic agonist formoterol protects endothelial cells against hypoxia/reoxygenation injury in vitro. Prospective controlled trial. University hospital research laboratory. Cultured human umbilical vein endothelial cells (HUVECs). Confluent HUVECs were sealed in a flow-through chamber mounted on an inverted microscope and perfused with a constant flow of Krebs medium. After 1 hr of equilibration, HUVECs underwent 2 hrs of hypoxia and 1 hr of reoxygenation. Cell death at the end of reoxygenation and reactive oxygen species formation were assessed with fluorescent probes propidium iodide and 2',7'-dichlorodihydrofluorescein diacetate, respectively. The effects of the beta2-adrenergic agonist formoterol, the beta2-adrenergic antagonist ICI 118,551 and the nitric oxide synthase inhibitor L-NNA were investigated. Statistical analysis was performed with analysis of variance followed by post hoc Fisher's test. Hypoxia/reoxygenation increased cell death (hypoxia/reoxygenation 29 +/- 4% vs. control 1 +/- 5%, p < .05) and endothelial reactive oxygen species production (hypoxia/reoxygenation 126 +/- 4% vs. control 108 +/- 4%, p < .05). Formoterol reduced cell death in a concentration-dependent manner (EC95 = 10 mol/L) and reduced endothelial reactive oxygen species production (hypoxia/reoxygenation + formoterol EC95 109 +/- 4% vs. hypoxia/reoxygenation 126 +/- 4%, p < .05). When added to formoterol EC95, ICI 118,551 and L-NNA abolished the formoterol-induced cell protection and reduced reactive oxygen species production. These results indicate that formoterol reduces endothelial cell death and reactive oxygen species production in this in vitro hypoxia/reoxygenation model. These effects are beta2-adrenergic specific and are partially mediated by nitric oxide synthase.Keywords
This publication has 39 references indexed in Scilit:
- Endothelium as an organ systemCritical Care Medicine, 2004
- High glucose‐induced oxidative stress and mitochondrial dysfunction in neuronsThe FASEB Journal, 2002
- Oxidative stress in septic shock and disseminated intravascular coagulationFree Radical Biology and Medicine, 2002
- Oxidative stress and endothelial activationCritical Care Medicine, 2002
- Endothelial cell dysfunction and abnormal tissue perfusionCritical Care Medicine, 2002
- Isoproterenol Inhibits Transcription of Cardiac Cytokine Genes Induced by Reactive Oxygen IntermediatesAnesthesiology, 2002
- Reactive species mechanisms of cellular hypoxia-reoxygenation injuryAmerican Journal of Physiology-Cell Physiology, 2002
- Activation of nitric oxide synthase by β2‐adrenoceptors in human umbilical vein endothelium in vitroBritish Journal of Pharmacology, 1999
- Catechol Adrenergic Agents Enhance Hydroxyl Radical Generation in Xanthine Oxidase Systems Containing Ferritin: Implications for Ischemia/ReperfusionArchives of Biochemistry and Biophysics, 1994
- Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species.Proceedings of the National Academy of Sciences, 1993